WA
XENT

Winfield Associates’s Intersect ENT, Inc XENT Stock Holding History

Winfield Associates’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$65K – 731
2017
Q4 		$65K Hold
2,000
– – 0.03% 179
2017
Q3 		$62K Hold
2,000
– – 0.03% 180
2017
Q2 		$56K Hold
2,000
– – 0.03% 187
2017
Q1 		$34K Buy
+2,000
New +$28K 0.02% 213

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winfield Associates's XENT Position: Q1 2018 in Review

Winfield Associates sold out of Intersect ENT, Inc (XENT) in Q1 2018, closing a stake of 2,000 shares — an estimated $65K sold.

Winfield Associates first reported a position in XENT in Q1 2017 and held it in 4 quarters. The position peaked at $65K in Q4 2017. 172 funds tracked by Wall St. Rank hold XENT as of Q1 2018.

  • Winfield Associates reported no remaining Intersect ENT, Inc position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 2,000 Intersect ENT, Inc shares in Q1 2018, an estimated $65K.
  • Winfield Associates first reported a position in Intersect ENT, Inc in Q1 2017 and held it in 4 quarters.
  • Winfield Associates's Intersect ENT, Inc position peaked at $65K in Q4 2017.
  • 172 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.